Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Anthony Paul Conley"'
Autor:
Neeta Somaiah, J Andrew Andrew Livingston, Vinod Ravi, Heather Y. Lin, Behrang Amini, Luisa Maren Solis, Anthony Paul Conley, Maria Alejandra Zarzour, Joseph Aloysius Ludwig, Ravin Ratan, Wei-Lien Wang, Dejka M. Araujo, Shreyaskumar Patel, Christina Lynn Roland, Alexander J. Lazar, Richard Greg Gorlick, Edwin R. Parra, Cara L. Haymaker
Publikováno v:
Journal of Clinical Oncology. 40:TPS11594-TPS11594
TPS11594 Background: Anti-PD 1/PD-L1 blockade alone or in combination with anti-CTLA4 have yielded suboptimal results in most sarcoma subtypes. CD73, an ectonucleotidase, catalyzes the rate-limiting step for adenosine production in the extracellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6399cc1d14e3527a8324e56d9f7ed676
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11594
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11594
Autor:
Blessie Elizabeth Nelson, Sadia Saleem, Senthil Damodaran, Neeta Somaiah, Sarina Anne Piha-Paul, Julia Ann Moore, Bulent Yilmaz, Daniel D. Karp, Ecaterina Elena Dumbrava, Apostolia Maria Tsimberidou, David S. Hong, Jordi Rodon Ahnert, Daniel J. Booser, Nuhad K. Ibrahim, Anthony Paul Conley, Priya Bhosale, Cristhiam Mauricio Rojas Hernandez, Debu Tripathy, Aung Naing, Funda Meric-Bernstam
Publikováno v:
Journal of Clinical Oncology. 40:3108-3108
3108 Background: Selinexor (KPT-330) is potent inhibitor of Exportin-1. In vitro, Selinexor was found to be synergistic with eribulin in triple negative breast cancer (TNBC) cell lines and enhanced antitumor activity of eribulin in TNBC patient-deriv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3d3afec55970a718ad6fd4c125a14d0
https://doi.org/10.1200/jco.2022.40.16_suppl.3108
https://doi.org/10.1200/jco.2022.40.16_suppl.3108
Autor:
Michael Nakazawa, J Andrew Andrew Livingston, Andrew Justin Bishop, Maria Alejandra Zarzour, Neeta Somaiah, Ravin Ratan, Jonathan Benjamin Gill, Elizabeth Urquiola, Kristi Posey, Beverly Ashleigh Guadagnolo, Richard Greg Gorlick, Robert S. Benjamin, Shreyaskumar Patel, Anthony Paul Conley
Publikováno v:
Journal of Clinical Oncology. 40:e23548-e23548
e23548 Background: Rhabdomyosarcomas are the most common soft tissue sarcoma in children, and the prognosis of pediatric ARMS has improved with the use of multi-modality therapies. However, ARMS in adults is rare, and long-term outcomes continue to b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ae204766af94b98670d7e5871981fd2a
https://doi.org/10.1200/jco.2022.40.16_suppl.e23548
https://doi.org/10.1200/jco.2022.40.16_suppl.e23548
Autor:
Prapassorn Thirasastr, Cissimol Joseph, Dejka M. Araujo, Robert S. Benjamin, Anthony Paul Conley, J Andrew Andrew Livingston, Joseph Aloysius Ludwig, Shreyaskumar Patel, Ravin Ratan, Vinod Ravi, Maria Alejandra Zarzour, Xiao Zhou, Neeta Somaiah
Publikováno v:
Journal of Clinical Oncology. 40:11542-11542
11542 Background: Ripretinib (R) is approved for 4th line treatment of GIST based on superior PFS and OS compared to placebo in a phase 3 study, with RR of 11.8% and PFS of 6.3 months (mo). In addition to having high potency against PDGFRA D842V, ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7ce285fbeee8c1b0b9f36fdb673b0b8a
https://doi.org/10.1200/jco.2022.40.16_suppl.11542
https://doi.org/10.1200/jco.2022.40.16_suppl.11542
Autor:
Sarina Anne Piha-Paul, Binghe Xu, Kanwal Pratap Singh Raghav, Funda Meric-Bernstam, Filip Janku, Ecaterina Elena Dumbrava, Siqing Fu, Daniel D. Karp, Jordi Rodon Ahnert, Anthony Paul Conley, Frank Mott, Jaffer A. Ajani, David S. Hong, Ying Fan, Peng Peng, Wendy J. Levin, Brenda Ngo, Qinhua Cindy Ru, Frank Wu, Milind M. Javle
Publikováno v:
Journal of Clinical Oncology. 40:3013-3013
3013 Background: TT-00420 is a spectrum-selective multi-kinase inhibitor that targets cell proliferation, angiogenesis, and immune-oncology pathways by inhibiting Aurora kinases A/B and Janus kinases (JAK) involved in cytokine signaling and receptor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e49dc400401329e84aaafd6e1395838f
https://doi.org/10.1200/jco.2022.40.16_suppl.3013
https://doi.org/10.1200/jco.2022.40.16_suppl.3013
Autor:
Sant P. Chawla, Garrett Thomas Wasp, Dale Randall Shepard, Jean-Yves Blay, Robin Lewis Jones, Silvia Stacchiotti, Peter Reichardt, Hans Gelderblom, Javier Martin-Broto, Brendan Eckelman, Michelle Darling, Vasily Andrianov, Anthony Paul Conley
Publikováno v:
Journal of Clinical Oncology. 40:TPS11582-TPS11582
TPS11582 Background: Chondrosarcomas (CS) are the third most common type of primary bone cancer after myeloma and osteosarcoma. Conventional CS represent 85–90% of all cases and are typically treated with surgical resection. However, there are no a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8d10ae2ba9a3bc211763f921b6cc93e
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11582
https://doi.org/10.1200/jco.2022.40.16_suppl.tps11582
Autor:
Mohamad Adham Salkeni, Anthony Paul Conley, James Lin Chen, Elizabeth J. Davis, Melissa Amber Burgess, Albiruni Ryan Abdul Razak, Nancy Moore, Katherine V. Ferry-Galow, Kristin K. Fino, King Leung Fung, Ralph E. Parchment, Jared C. Foster, Christina Rosenberger, Geraldine Helen O'Sullivan Coyne, Naoko Takebe, Elad Sharon, James H. Doroshow, Alice P. Chen
Publikováno v:
Journal of Clinical Oncology. 40:11528-11528
11528 Background: Chondrosarcoma is one of the most common bone malignancies in adults, and the third most common in pediatric patients (pts). The most prevalent subtype, conventional chondrosarcoma, is a slow growing tumor that is historically known
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::604b5f9eac5d22a82039ab9516e3abd0
https://doi.org/10.1200/jco.2022.40.16_suppl.11528
https://doi.org/10.1200/jco.2022.40.16_suppl.11528